Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: HUC3-637, HUC3-637-R.
- Who it may be relevant to
- Registry conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Overview
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
Interventions
- Drug HUC3-637
Ophthalmic solution instilled directly into the eye (topical ocular administration) - Drug HUC3-637-R
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Primary outcome measures
- Mean change in diurnal IOP [Time frame: 12 week]
Eligibility criteria
Inclusion criteria
- Adults aged 19 years and older
- Participants diagnosed with POAG or OH
- Have fully explained and understood the study and have voluntarily given written informed consent.
Exclusion criteria
- Acute or chronic angle-closure glaucoma
- Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
South Korea · 1 center
- Kangbuk Samsung Hospital — Seoul
Identifiers
NCT: NCT07335211 · HUC3-637